Disease block
L40-L45 – Papulosquamöse Hautkrankheiten
- Chapter XII: Krankheiten der Haut und der Unterhaut
27Decisions
46Patient groups
Added benefit by patient group
- Considerable7
- Minor8
- Non-quantifiable1
- Not proven30
Diseases in this disease block
- L40 Psoriasis 27 decisions
Decisions, newest first
Each decision lists only the patient groups coded with a disease in this disease block.
- 2026-06-18TremfyaGuselkumabNot proven
- 2026-03-19TaltzIxekizumabNot proven
- 2025-05-15OtezlaApremilastNot proven
- 2024-05-02OlumiantBaricitinibNot proven
- 2023-12-21BimzelxBimekizumabNot proven: 2 of 2 patient groups
- 2023-10-05SotyktuDeucravacitinibNot proven: 2 of 2 patient groups
- 2023-07-20SpevigoSpesolimabNot proven
- 2023-01-05CosentyxSecukinumabNot proven
- 2022-05-19SkyriziRisankizumabNot proven: 2 of 2 patient groups
- 2022-03-03XeljanzTofacitinibNot proven
- 2022-03-03BimzelxBimekizumabMinor: 2 of 2 patient groups
- 2021-07-15RinvoqUpadacitinibConsiderable: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2021-05-20TremfyaGuselkumabNot proven: 2 of 2 patient groups
- 2021-02-18CosentyxSecukinumabMinor
- 2021-02-18CosentyxSecukinumabMinor: 1 of 3 patient groupsNot proven: 2 of 3 patient groups
- 2021-01-21TaltzIxekizumabNot proven
- 2019-11-22SkyriziRisankizumabConsiderable: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2019-05-02IlumetriTildrakizumabNot proven: 2 of 2 patient groups
- 2019-02-21XeljanzTofacitinibMinor: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2018-08-16TaltzIxekizumabMinor: 1 of 3 patient groupsNot proven: 2 of 3 patient groups
- 2018-05-17TremfyaGuselkumabConsiderable: 2 of 2 patient groups
- 2018-03-16SkilarenceDimethylfumaratNot proven: 2 of 2 patient groups
- 2018-03-01KyntheumBrodalumabNon-quantifiable: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2017-08-17CosentyxSecukinumabConsiderable
- 2017-08-17TaltzIxekizumabConsiderable: 1 of 2 patient groupsMinor: 1 of 2 patient groups
- 2015-11-27CosentyxSecukinumabConsiderable: 1 of 2 patient groupsMinor: 1 of 2 patient groups
- 2015-08-06OtezlaApremilastNot proven: 2 of 2 patient groups
Data status: 2026-10-29